JP MORGAN/CALL/BOSTON SCIENTIFIC/60/0.1/20.06.25 | Delayed Börse Stuttgart 04:07:49 2024-07-16 am EDT | ||
| 2.22 EUR | -2.63% |
|
| Current month | +3.64% | ||
| 1 month | +3.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 2.22 | -2.63% |
| 24-07-15 | 2.28 | +7.04% |
| 24-07-12 | 2.13 | -1.84% |
| 24-07-11 | 2.17 | +2.36% |
| 24-07-10 | 2.12 | +1.92% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 04:07 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JB7GT8 |
| ISIN | DE000JB7GT81 |
| Date issued | 2023-12-06 |
| Strike | 60 $ |
| Maturity | 2025-06-20 (340 Days) |
| Parity | 10 : 1 |
| Emission price | 0.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.31 € |
|---|---|
| Lowest since issue | 0.9 € |
| Spread | 0.1 € |
| Spread % | 4.31% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
78.02
USD
Average target price
83.68
USD
Spread / Average Target
+7.26%
- Stock Market
- Warrants
- Warrant
